The U.S. Food and Drug Administration approved Flexion Therapeutics Inc.'s non-opioid drug Zilretta, an intra-articular injection for osteoarthritis knee pain.
The FDA approval is based upon data from Flexion's pivotal phase 3 clinical trial.
Zilretta's label also includes the results from a trial that examined blood glucose concentrations in patients with type 2 diabetes. The trial found that Zilretta may avoid the spikes in blood sugar associated with the use of corticosteroid treatment in patients with both knee pain and diabetes.
Flexion expects Zilretta will be available in the U.S. by the end of October.